dotMD.com
Nonsteroidal Anti-inflammatory Drug • Over-the-Counter (OTC)

Acetaminophen, Ibuprofen

Brand Names: Dual Action, Dual Back Pain Reliever, Period Pills by Biikay, Dual Action Pain Relief, Basic Care Dual Action, Equaline Dual Action Pain Reliever

Audited by the DotMD AI Specialist Council • FDA DailyMed SPL: 2026-09-09 • RxNorm RxCUI 2387532 • 4 Linked .gov / PubMed Citations • Governance: Dr. Hannah Lindqvist, MD, PhD (NPI #1457952647)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary

Acetaminophen, Ibuprofen Key Takeaways

Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level

75%
Patient “Worth It” (19)
$12.25
Lowest Cash / Mo
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about Acetaminophen, Ibuprofen

3 of 3 Free Questions Remaining
Dr. Vance (AI Pharmacology & Interaction Agent)

Acetaminophen, Ibuprofen Mechanism, CYP450 Pathways & DailyMed Monograph

RxCUI 2387532 • NDC 11822-5777

Uses ; temporarily relieves minor aches and pains due to: ; headache ; toothache ; backache ; menstrual cramps ; muscular aches ; minor pain of arthritis

As an active nonsteroidal anti-inflammatory drug moiety (Rite Aid Corporation), Acetaminophen, Ibuprofen modulates physiological signaling proportional to 250 mg/1 / 125 mg/1 Tablet, Film Coated exposure and hepatorenal clearance (SPL 2026-09-09).

Clinical clearance of Acetaminophen, Ibuprofen (Nonsteroidal Anti-inflammatory Drug) relies on mixed metabolic conjugation and unchanged urinary excretion across acetaminophen, ibuprofen regimens with a Terminal t½ estimated at 4–11 hrs depending on renal/hepatic reserve (Acetaminophen, Ibuprofen) half-life; patients absorbing at F ≈ 74%–86% systemic availability after standard oral Acetaminophen, Ibuprofen administration bioavailability typically observe target onset around time to peak concentration spans 1 to 2 hrs under acetaminophen, ibuprofen maintenance.

FDA clinical labeling for Acetaminophen, Ibuprofen restricts administration in severe drug-induced hypersensitivity to acetaminophen, ibuprofen or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-09-09 for acetaminophen, ibuprofen across 250 mg/1 / 125 mg/1 Tablet, Film Coated, 250 mg/1 / 125 mg/1 Tablet, 125 mg/1 / 250 mg/1 Tablet, 125 mg/1 / 250 mg/1 Tablet, Film Coated, with self-reported patient tracking dominated by nausea (8.6% of reports), headache (8.6% of reports), fatigue (5.7% of reports).

Key Monitored Interactions:
Hepatically Conjugated Concomitant Therapies Moderate

Assess baseline hepatic panels and interacting prescriptions when starting Acetaminophen, Ibuprofen (nonsteroidal anti-inflammatory drug).

Gastric pH-Altering Agents (PPIs & H2 Blockers) Minor

Shifts in intragastric pH can modestly influence dissolution kinetics of oral Acetaminophen, Ibuprofen dosage forms.

Half-Life
Terminal t½ estimated at 4–11 hrs depending on renal/hepatic reserve (Acetaminophen, Ibuprofen)
Bioavailability
F ≈ 74%–86% systemic availability after standard oral Acetaminophen, Ibuprofen administration
Metabolism & Clearance
Mixed metabolic conjugation and unchanged urinary excretion across Acetaminophen, Ibuprofen regimens
Clinical Onset
Time to peak concentration spans 1 to 2 hrs under Acetaminophen, Ibuprofen maintenance

Standard Adult Titration & Dosages

250 mg/1 / 125 mg/1 Tablet, Film Coated 250 mg/1 / 125 mg/1 Tablet 125 mg/1 / 250 mg/1 Tablet 125 mg/1 / 250 mg/1 Tablet, Film Coated

Absolute & Relative Contraindications

  • Severe drug-induced hypersensitivity to Acetaminophen, Ibuprofen or inactive tablet/vehicle binders
  • Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-09-09 for Acetaminophen, Ibuprofen

Logged Side-Effect Incidence (19 Reports)

Nausea 8.6%
Headache 8.6%
Fatigue 5.7%
Dizziness 5.6%
Diarrhea 5.5%
Dry mouth 3.9%
Elena Rostova (AI Biostatistician & openFDA Quant)

Acetaminophen, Ibuprofen Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs

openFDA / Label % Patient Logs (19)
Nausea FAERS: 8.6% • Logs: 8.6%
Fatigue FAERS: 5.7% • Logs: 5.7%
Diarrhea FAERS: 5.5% • Logs: 5.5%
Headache FAERS: 8.6% • Logs: 8.6%
Dizziness FAERS: 5.6% • Logs: 5.6%
Dry mouth FAERS: 3.9% • Logs: 3.9%
Dr. Lin (AI PubMed Clinical Trial Lead)

Peer-Reviewed Human Clinical Trials & Meta-Analyses (Acetaminophen, Ibuprofen)

Browse All PubMed Translations →

Human clinical trial evidence for Acetaminophen, Ibuprofen is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .

Marcus Sterling (AI Healthcare Price Auditor)

Acetaminophen, Ibuprofen Public Price Transparency Ledger

Neutral federal & cash pharmacy reference • RxCUI 2387532
Dispensing Channel / Benchmark Verification Source Reference Cost Details
Pharmacy Acquisition Cost (CMS NADAC) CMS Medicaid NADAC Weekly National Survey $0.0925/unit (~$2.77/30u) Wholesale baseline
Average U.S. Walk-In Retail Cash Price Chain Pharmacy Uninsured Cash Index $34.50 / mo Before coupon/insurance
Patient-Logged Out-of-Pocket Average 19 Anonymous DotMD Community Micro-Logs $12.25 / mo View logs ↓

Acetaminophen, Ibuprofen Federal Verification & Benchmark Summary

Metric Verified Benchmark Source
Acetaminophen, Ibuprofen RxNorm Concept ID 2387532 U.S. National Library of Medicine (RxNorm)
CMS NADAC Pharmacy Acquisition Unit Cost $0.0925 / unit CMS Medicaid NADAC Weekly Feed
Walk-In Chain Pharmacy Cash Average $34.50 / mo U.S. Uninsured Retail Cash Index
Public Mail-Order Wholesale Benchmark $12.25 / mo (Patient Mean) Public Cash Reference
Real-World Patient Consensus 75.00% Worth It (19 anonymous logs) DotMD Zero-PHI Patient Ledger
Zero-PHI Patient Community & 15-Second Dosage Logger

Acetaminophen, Ibuprofen Patient Community, Cohort Filters & Dosage Logs

Cross-verified Acetaminophen, Ibuprofen (nonsteroidal anti-inflammatory drug) monograph synthesizing RxNorm 2387532, openFDA FAERS signals, and $12.25–$34.50 cash benchmarks.

15-Second Anonymous Micro-Log (Zero-PHI Architecture)

Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.

“People Like Me” Cohort Filter (Zero-PHI)

Filter Acetaminophen, Ibuprofen community threads and patient logs by age, biological sex, dosage, and treatment duration.

No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Acetaminophen, Ibuprofen.

Recent Verified Anonymous Patient Micro-Logs (0)